BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.60 Consensus Target Price from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned an average recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.60.

BCRX has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C grew its holdings in BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after acquiring an additional 3,140,804 shares during the period. Geode Capital Management LLC grew its position in BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after purchasing an additional 127,708 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after purchasing an additional 481,359 shares during the last quarter. Two Sigma Advisers LP raised its position in BioCryst Pharmaceuticals by 13.6% in the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after acquiring an additional 261,500 shares during the period. Finally, Rice Hall James & Associates LLC increased its position in BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after buying an additional 84,102 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $7.83 on Friday. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.88. The firm has a market capitalization of $1.62 billion, a PE ratio of -12.84 and a beta of 1.79. The business’s fifty day moving average price is $7.62 and its two-hundred day moving average price is $7.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.19) EPS. Equities research analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.